In the BioHarmony Drug Report Database

"Preview" Icon

Avatrombopag

Doptelet (avatrombopag) is a small molecule pharmaceutical. Avatrombopag was first approved as Doptelet on 2018-05-21. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. It is known to target thrombopoietin receptor. Doptelet’s patents are valid until 2025-05-05 (FDA).

 

Trade Name

 

Doptelet
 

Common Name

 

avatrombopag
 

ChEMBL ID

 

CHEMBL2103883
 

Indication

 

thrombocytopenia
 

Drug Class

 

Thrombopoetin agonists

Image (chem structure or protein)

Avatrombopag structure rendering